Risk factors, resistance profiles, and clinical outcomes of Klebsiella pneumoniae infection in cancer patients: a retrospective study
Frontiers in Cellular and Infection Microbiology · 2026
DOI: 10.3389/fcimb.2026.1908965 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2026. Verfasst von Shulei Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, The Fourth Affiliated Hospital of Anhui Medical University, ChaoHu, Anhui, China. Hauptthemen laut MEDLINE: Klebsiella Infections, Klebsiella pneumoniae, Neoplasms. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Cancer patients are highly susceptible to Klebsiella pneumoniae (KP) infection, yet integrated analyses considering infection-site resistance patterns, cancer-type heterogeneity, and host risk factors remain limited.
Methods
We retrospectively analyzed 300 adult cancer patients treated between October 2023 and November 2024, including 153 with KP infection and 147 uninfected controls. Data on demographics, comorbidities, invasive procedures, laboratory findings, antimicrobial resistance, treatment patterns, and outcomes were collected. Independent risk factors were identified using multivariable logistic regression, and a predictive nomogram was developed and validated.
Results
The respiratory tract was the most common infection site (60.8%), followed by urinary tract (14.4%) and bloodstream (10.4%). Urinary isolates exhibited the highest rates of multidrug-resistant KP (MDR-KP, 69.6%) and extended-spectrum β-lactamase-producing KP (ESBL-KP, 60.9%). Multivariate analysis identified hypoproteinemia (odds ratio [OR] = 2.233, 95% confidence interval [CI] 1.222-4.077, P = 0.009), percutaneous catheter drainage (OR = 1.995, 95% CI 1.050-3.790, P = 0.035), and radiotherapy (OR = 3.556, 95% CI 1.507-8.392, P = 0.004) as independent factors associated with KP infection. Recent hospitalization was independently associated with both MDR-KP (OR = 3.257, 95% CI 1.227-8.649, P = 0.018) and ESBL-KP (OR = 3.101, 95% CI 1.151-8.355, P = 0.025). A nomogram incorporating these predictors demonstrated strong discriminative ability (area under the curve = 0.702) and clinical utility.
Conclusion
Statistical models indicate that KP infection in cancer patients is likely linked to host immunity, invasive interventions, and treatment exposures; the nomogram can assist in early risk stratification and facilitate tailored stewardship.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory, The Fourth Affiliated Hospital of Anhui Medical University, ChaoHu, Anhui, China.
- Department of Blood Transfusion, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
- Department of Anesthesiology, The Fourth Affiliated Hospital of Anhui Medical University, ChaoHu, Anhui, China.
Zitieren
APA
Zhang, S., Wang, J., Zhang, S., Lu, S., Chang, M., Xu, W., Zhang, Q., & Zhu, M. (2026). Risk factors, resistance profiles, and clinical outcomes of Klebsiella pneumoniae infection in cancer patients: a retrospective study. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2026.1908965
Vancouver
Zhang S, Wang J, Zhang S, Lu S, Chang M, Xu W, et al. Risk factors, resistance profiles, and clinical outcomes of Klebsiella pneumoniae infection in cancer patients: a retrospective study. Frontiers in Cellular and Infection Microbiology. 2026. doi:10.3389/fcimb.2026.1908965
BibTeX
@article{Zhang2026,
author = {Zhang, Shulei and Wang, Jingwen and Zhang, Shuo and Lu, Shuping and Chang, Miaosu and Xu, Wei and Zhang, Qingmei and Zhu, Mei},
title = {Risk factors, resistance profiles, and clinical outcomes of Klebsiella pneumoniae infection in cancer patients: a retrospective study},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2026},
doi = {10.3389/fcimb.2026.1908965}
}
EUVIMED